This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
20 Jul 2011

CEL-SCI and Teva Expand Licensing Agreement for Cancer Drug Multikine

Teva's exclusive license to market and distribute Multikine in Israel and Turkey will be extended to include Croatia and Serbia. The parties will share revenue generated from all four countries.

CEL-SCI Corporation announced Tuesday that it has expanded the licensing agreement with Teva Pharmaceutical Industries Ltd. for its cancer drug Multikine.

 

Under the agreement, Teva's exclusive license to market and distribute Multikine, the Company's investigational Phase III drug for the treatment of head and neck cancer, in Israel and Turkey will be extended to include Croatia and Serbia.

 

Teva is currently funding a part of the global Phase III clinical study at three clinical sites in Israel. Teva will be responsible for the costs of registering and selling the product in Serbia and Croatia and will pay CEL-SCI milestone payments upon approval of Multikine. The parties will share revenue generated from all four countries.

<

Related News